Home/Pipeline/COVID-19 Conjugate Vaccine

COVID-19 Conjugate Vaccine

COVID-19

Not Disclosed (Research/Preclinical)Active

Key Facts

Indication

COVID-19

Phase

Not Disclosed (Research/Preclinical)

Status

Active

Company

Inventprise

About Inventprise

Founded in 2014 (originating from 2012), Inventprise is a private, clinical-stage biotech based in Redmond, Washington, developing novel conjugate vaccines using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker platform. Its lead candidate is a 25-valent pediatric pneumococcal conjugate vaccine (IVT PCV-25), and its pipeline includes Phase 1/2 candidates for Group B Streptococcus (GBS), Shigella, Klebsiella, and COVID-19. Led by vaccine industry veteran Dr. Subhash Kapre, the company has built state-of-the-art manufacturing capacity and grown to over 200 employees, positioning itself to address significant global infectious disease burdens.

View full company profile

Therapeutic Areas

Infectious Diseases

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active